Chronic prostatitis equals high financial costs, according to research by the Chronic Prostatitis Collaborative Research Network (Arch Intern Med 2004; 164:1231-6).
Dr. Schuster highlights the FDA approval of imaging agent flotufolastat F 18 in prostate cancer
June 22nd 2023"We're excited that the FDA approval of this radiotracer gives us yet more tools at our disposal to diagnose prostate cancer in all its forms, from early to late in the disease process," says David M. Schuster, MD, FACR.
Demystifying Vector-Based Intravesical Gene Therapy for NMIBC: A New Frontier
November 28th 2023Neal Shore, MD, FACS, is a U.S. Chief Medical Officer at GenesisCare USA and Medical Director of the Carolina Urologic Research Center. He also was an investigator on the Phase 2 and 3 studies in the clinical trial program for nadofaragene firadenovec-vncg.